The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis
Abstract Background Brain metastases (BM) are common complications of metastatic cancer and typically occur in patients with melanoma. This study aims to investigate the dabrafenib plus trametinib for patients diagnosed with melanoma brain metastasis (MBM). Method This review adhered to the Preferre...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02778-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725087424446464 |
|---|---|
| author | Mohammad Amin Habibi Mohammad Sina Mirjani Bardia Hajikarimloo Mohsen Dashti Afsaneh Ghasemzadeh Seyed Hesam Hojjat Mohammad Shahir Eftekhar Kosar Doraghi Yalda Ghazizadeh Fateme Aghaei Shaghayegh Karami Mehrshad Edalat Farhang Rashidi Sajjad Ahmadpour Sina Ahmadi |
| author_facet | Mohammad Amin Habibi Mohammad Sina Mirjani Bardia Hajikarimloo Mohsen Dashti Afsaneh Ghasemzadeh Seyed Hesam Hojjat Mohammad Shahir Eftekhar Kosar Doraghi Yalda Ghazizadeh Fateme Aghaei Shaghayegh Karami Mehrshad Edalat Farhang Rashidi Sajjad Ahmadpour Sina Ahmadi |
| author_sort | Mohammad Amin Habibi |
| collection | DOAJ |
| description | Abstract Background Brain metastases (BM) are common complications of metastatic cancer and typically occur in patients with melanoma. This study aims to investigate the dabrafenib plus trametinib for patients diagnosed with melanoma brain metastasis (MBM). Method This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed, Embase, Scopus, and Web of Science were searched until January 1, 2025. Data on the neurological progression-free survival (PFS), overall survival (OS), radiological response rate, whether intracranial and total, and adverse events were collected. Quality assessment of the studies was conducted using the Newcastle–Ottawa Scale (NOS). The STATA version 17.0. has been used for analysis of the outcomes. Results Eleven studies met the inclusion criteria. Our results showed pooled 6-month OS rate of 76% (95% CI [69–84%]), 1-year OS of 45% (95% CI [38–51%]), 6-month PFS rate of 46% (95% CI [40–52%]), 1-year PFS of 22% (95% CI [13–30%]), disease control rate (DCR) of 71% (95% CI [61–80%]), overall response rate (ORR) of 45% (95% CI [33–57%]), complete response rate (CRR) of 4% (95% CI [0–11%]), partial response rate (PRR) of 47% (95% CI [31–63%]), progressive disease rate (PDR) of 29% (95% CI [13–44%]), and stable disease rate (SDR) of 21% (95% CI [14–27%]). The pooled intracranial CRR, intracranial PRR, intracranial SDR, and intracranial PDR were 4% [95% CI: 1–8%], 42% [95% CI: 32–53%], 24% [95% CI: 18–31%], and 24% [95% CI: 13–34%], respectively. Conclusion These findings underscore the effectiveness of dabrafenib plus trametinib in managing MBM, offering potential benefits in disease control and patient outcomes. |
| format | Article |
| id | doaj-art-d81bcdcb7f494e1185344061ca9ff1de |
| institution | DOAJ |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-d81bcdcb7f494e1185344061ca9ff1de2025-08-20T03:10:34ZengSpringerDiscover Oncology2730-60112025-06-0116112810.1007/s12672-025-02778-8The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysisMohammad Amin Habibi0Mohammad Sina Mirjani1Bardia Hajikarimloo2Mohsen Dashti3Afsaneh Ghasemzadeh4Seyed Hesam Hojjat5Mohammad Shahir Eftekhar6Kosar Doraghi7Yalda Ghazizadeh8Fateme Aghaei9Shaghayegh Karami10Mehrshad Edalat11Farhang Rashidi12Sajjad Ahmadpour13Sina Ahmadi14Department of Neurosurgery, Shariati Hospital, Tehran University of Medical SciencesStudent Research Committee, Qom University of Medical SciencesDepartment of Neurological Surgery, University of VirginiaImmunology Research Center, Tabriz University of Medical SciencesImmunology Research Center, Tabriz University of Medical SciencesNorth Khorasan University of Medical SciencesDepartment of Surgery, School of Medicine, Shahid Beheshti Hospital, Qom University of Medical SciencesDepartment of Otolaryngology, Masih Daneshvari Hospital, Shahid Beheshti University of Medical SciencesStudent Research Committee, Shahid Beheshti University of Medical SciencesStudent Research Committee, Qom University of Medical SciencesSchool of Medicine, Tehran University of Medical SciencesDepartment of Medicine, Tehran Medical Branch, Islamic Azad UniversitySchool of Medicine, Tehran University of Medical SciencesPatient Safety Research Center, Clinical Research Institute, Urmia University of Medical SciencesCase Western Reserve UniversityAbstract Background Brain metastases (BM) are common complications of metastatic cancer and typically occur in patients with melanoma. This study aims to investigate the dabrafenib plus trametinib for patients diagnosed with melanoma brain metastasis (MBM). Method This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed, Embase, Scopus, and Web of Science were searched until January 1, 2025. Data on the neurological progression-free survival (PFS), overall survival (OS), radiological response rate, whether intracranial and total, and adverse events were collected. Quality assessment of the studies was conducted using the Newcastle–Ottawa Scale (NOS). The STATA version 17.0. has been used for analysis of the outcomes. Results Eleven studies met the inclusion criteria. Our results showed pooled 6-month OS rate of 76% (95% CI [69–84%]), 1-year OS of 45% (95% CI [38–51%]), 6-month PFS rate of 46% (95% CI [40–52%]), 1-year PFS of 22% (95% CI [13–30%]), disease control rate (DCR) of 71% (95% CI [61–80%]), overall response rate (ORR) of 45% (95% CI [33–57%]), complete response rate (CRR) of 4% (95% CI [0–11%]), partial response rate (PRR) of 47% (95% CI [31–63%]), progressive disease rate (PDR) of 29% (95% CI [13–44%]), and stable disease rate (SDR) of 21% (95% CI [14–27%]). The pooled intracranial CRR, intracranial PRR, intracranial SDR, and intracranial PDR were 4% [95% CI: 1–8%], 42% [95% CI: 32–53%], 24% [95% CI: 18–31%], and 24% [95% CI: 13–34%], respectively. Conclusion These findings underscore the effectiveness of dabrafenib plus trametinib in managing MBM, offering potential benefits in disease control and patient outcomes.https://doi.org/10.1007/s12672-025-02778-8BRAF inhibitorDabrafenibMEK inhibitorMelanomaMelanoma brain metastasisTrametinib |
| spellingShingle | Mohammad Amin Habibi Mohammad Sina Mirjani Bardia Hajikarimloo Mohsen Dashti Afsaneh Ghasemzadeh Seyed Hesam Hojjat Mohammad Shahir Eftekhar Kosar Doraghi Yalda Ghazizadeh Fateme Aghaei Shaghayegh Karami Mehrshad Edalat Farhang Rashidi Sajjad Ahmadpour Sina Ahmadi The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis Discover Oncology BRAF inhibitor Dabrafenib MEK inhibitor Melanoma Melanoma brain metastasis Trametinib |
| title | The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis |
| title_full | The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis |
| title_fullStr | The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis |
| title_full_unstemmed | The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis |
| title_short | The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis |
| title_sort | safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma a systematic review and meta analysis |
| topic | BRAF inhibitor Dabrafenib MEK inhibitor Melanoma Melanoma brain metastasis Trametinib |
| url | https://doi.org/10.1007/s12672-025-02778-8 |
| work_keys_str_mv | AT mohammadaminhabibi thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mohammadsinamirjani thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT bardiahajikarimloo thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mohsendashti thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT afsanehghasemzadeh thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT seyedhesamhojjat thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mohammadshahireftekhar thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT kosardoraghi thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT yaldaghazizadeh thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT fatemeaghaei thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT shaghayeghkarami thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mehrshadedalat thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT farhangrashidi thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT sajjadahmadpour thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT sinaahmadi thesafetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mohammadaminhabibi safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mohammadsinamirjani safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT bardiahajikarimloo safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mohsendashti safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT afsanehghasemzadeh safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT seyedhesamhojjat safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mohammadshahireftekhar safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT kosardoraghi safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT yaldaghazizadeh safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT fatemeaghaei safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT shaghayeghkarami safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT mehrshadedalat safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT farhangrashidi safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT sajjadahmadpour safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis AT sinaahmadi safetyandefficacyofdabrafenibplustrametinibforpatientswithbrainmetastaticmelanomaasystematicreviewandmetaanalysis |